TIDMERGO

RNS Number : 5093R

Ergomed plc

01 March 2019

PRESS RELEASE

FOR IMMEDIATE RELEASE

Total Voting Rights

Guildford, UK - 1 March 2019: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTRs), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 28 February 2019 consisted of 46,141,438 ordinary shares of 1p each, none of which were held in treasury. Each ordinary share in the capital of the Company carries one voting right.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

- Ends -

Enquiries:

 
 Ergomed plc                                              Tel: +44 (0) 1483 402 
                                                                            975 
 Miroslav Reljanovic (Executive Chairman) 
 Stuart Jackson (Chief Financial Officer) 
 
 Numis Securities Limited                             Tel: +44 (0) 20 7260 1000 
 Michael Meade / Freddie Barnfield (Nominated 
  Adviser) 
 James Black (Joint Broker) 
 
 
 Consilium Strategic Communications - for             Tel: +44 (0) 20 3709 5700 
  UK enquiries 
 Chris Gardner / Mary-Jane Elliott                  ergomed@consilium-comms.com 
 Matthew Neal / Olivia Manser 
 
 MC Services - for Continental European enquiries        Tel: +49 211 5292 5222 
 Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRTPMRTMBATBJL

(END) Dow Jones Newswires

March 01, 2019 02:00 ET (07:00 GMT)

Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ergomed Charts.
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ergomed Charts.